Seven Bridges & e-NIOS Partnership to Break the Biomarker Bottleneck

CAMBRIDGE, Mass. and ATHENS, Greece, Sept. 11, 2018 /PRNewswire/ -- Seven Bridges, the leading biomedical data platform and analytics company, and e-NIOS, a biological knowledge discovery start-up, announced a strategic partnership towards data-driven discovery of biomarker signatures. Derivation of robust biomarkers from next generation sequencing and multi-omic data is currently a major bottleneck in precision medicine initiatives. This bottleneck continues to limit the transformation of genomic information into biomedical insights that will improve clinical outcomes through more efficient drug target discovery and more effective patient stratification.

Together, we are leveraging machine learning and physiology to improve and partially automate interpretation of potential biomarkers. Currently, interpretation is largely performed manually, relying on expert decisions. Human experts are both costly and inconsistent. Our partnership will develop efficient and standardized interpretation frameworks which harness the inherent complexity of molecular networks. This partnership has the potential to shift from listing all statistical correlations towards focusing on a smaller set of causal associations.

e-NIOS' innovative technology enables unsupervised, intelligent translation of -omics data through BioInfoMiner, a cloud platform that resolves biological complexity and derives molecular signatures suitable for data-driven interpretation in different conditions, physiological states and datasets. Additionally, it allows the integration of different -omic layers (genomic, epigenomic, transcriptomic, proteomic, variants). BioInfoMiner can also drive discovery in studies related to plant and microbial systems.

According to e-NIOS' co-founder Aristotelis Chatziioannou (CEO), "e-NIOS and Seven Bridges share the same vision for data-driven, streamlined computational genomics, integrating all steps from raw data to actionable biological interpretation. The Seven Bridges Platform is a valuable, high-performance cloud environment for the deployment of complex workflows and streamlined processing of massive, genomic datasets. Seven Bridges has been an excellent technological partner for our company as we work together to enable innovative, automated, data-driven biomarker industrial services and applications in the area of precision medicine."  

As Brandi Davis-Dusenbery, CEO of Seven Bridges, explained, "e-NIOS' technology has the unique ability to combine biological network information with data-driven models. Here we bring together the technical and scientific strengths of both companies to provide a complete solution for the prediction of biomarker associations from raw data. Our strategic partnership supports Seven Bridges' mission to connect the world's biomedical information and rapidly transform it into actionable information."

About Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development, and precision medicine. Thousands of researchers in government, biotech, and academia use Seven Bridges, including leading global pharmaceutical companies and national genomics projects such as the U.S. National Cancer Institute-funded Cancer Genomics Cloud, the Gabriella Miller Kids' First Data Center, the Million Veteran Program, and the U.S. National Institutes of Health Data Commons Pilot. To find out more, contact us.

About e-NIOS

e-NIOS Applications P.C. is a spin-off company of the National Hellenic Research Foundation, founded by a multidisciplinary team with expertise in the fields of Bioinformatics, Genomics, Artificial Intelligence, Data Mining, Operational Research and Decision Support Systems. The company participates in many funded EU Horizon 2020 Research & Innovation networks and has developed sustainable international collaborations with partners such as the National University of Ireland, Galway, the French National Institute of Health and Medical Research (INSERM) the German Anticancer Institute Deutsches Krebsforschungszentrum  (DKFZ, Heidelberg) and many Universities and research groups across Europe. Research results obtained through e-NIOS technology have been published in high impact journals (EMBO Molecular Medicine, Cell Metabolism, FASEB, Scientific Reports and Nature Communications). e-NIOS recently filed a joint international patent with INSERM, France, entitled "Method of therapy selection for patients suffering from Glioblastoma", exploiting results generated through BioInfoMiner. To find out more, contact us.

Media Contact: [email protected]

SOURCE Seven Bridges Genomics Inc.